The low-density lipoprotein cholesterol lowering is an ineffective surrogate marker of statin responsiveness to predict cardiovascular outcomes: The 10-year experience of matched population (a STROBE-compliant article)

Myung Han Hyun, Jae Won Jang, Byoung Geol Choi, Jin Oh Na, Cheol Ung Choi, Jin Won Kim, Eung Ju Kim, Seung Woon Rha, Chang Gyu Park, Eunmi Lee, Hong Seog Seo

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Statins therapy decrease both low-density lipoprotein cholesterol (LDL-C) levels and the risk of atherosclerotic cardiovascular disease (ASCVD) with considerable individual variability. Whether the amount of LDL-C lowering is a surrogate maker of statin responsiveness to ASCVD prevention has not been fully investigated. Among 2352 eligible patients with statin prescriptions in a cardiovascular center between January 2005 and February 2014, one-third of patients (33%) on statin therapy failed to achieve effective reductions in LDL-C (LDL-C level reduction of less than 15%). By using, propensity-score matched population (480 pairs, n=960), the 5-year cumulative incidences of total major adverse cardiac events (MACE) were evaluated. The 5-year total MACE did not differ between normal cholesterol responders and non-responders (15.4% vs 16.1%, respectively; P=.860). In the subgroup analysis, male sex, older age, percutaneous coronary intervention, and heart failure were positive predictors, and dyslipidemia at the beginning of statin therapy was the only negative predictor of MACE in the 5-year follow-up (all P value<.05). However, cholesterol responsiveness after statin therapy did not influence the incidence of MACE (P=.860). The amount of LDL-C lowering did not predict beneficial effect on clinical outcomes of ASCVD after statin therapy. This result supports that given statin therapy, total ASCVD risk reduction should be tailored, which may not dependent to adherence to degree of LDL-C lowering or LDL-C goal based treatment.

Original languageEnglish
Article numbere18510
JournalMedicine (United States)
Volume98
Issue number51
DOIs
Publication statusPublished - 2019 Dec 1

Bibliographical note

Publisher Copyright:
© 2019 the Author(s).

Keywords

  • coronary artery disease
  • disease progression
  • low-density lipoprotein cholesterol
  • statin responsiveness

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'The low-density lipoprotein cholesterol lowering is an ineffective surrogate marker of statin responsiveness to predict cardiovascular outcomes: The 10-year experience of matched population (a STROBE-compliant article)'. Together they form a unique fingerprint.

Cite this